Here’s a quick look at a 2017 analysis of the Alzheimer’s drug pipeline.
Twenty-seven Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials are expected to launch in the next five years, according to a revised Alzheimer’s pipeline analysis presented by ResearchersAgainstAlzheimer’s (RA2), a network of top scientists in the field of Alzheimer’s research. That’s a significant increase in the number of trials since last year and scientists are hopeful that this new momentum will yield real results. There are currently 23 drugs in Phase II and III trials targeting amyloid protein buildup in the brain and 28 drugs targeting neurotransmitter activity.
There are currently 23 drugs in Phase II
and III trials targeting amyloid protein buildup
in the brain and 28 drugs targeting neurotransmitter activity.
Deaths from dementia continue to rise, with the a recent report by the Centers for Disease Control and Prevention stating that Alzheimer’s deaths in the U.S. increased by 55 percent from 1999-2014. Despite this worrying trend, a new treatment for Alzheimer’s hasn’t been approved by the FDA since 2003 and the European Union since 2002.
These late-stage Alzheimer’s drugs provide much-needed hope to those with Alzheimer’s and their caregivers who are desperate for a treatment or cure. According to the analysis, six drugs will conclude Phase III trials in 2017.
George Vradenburg, UsAgainstAlzheimer’s Co-Founder and Chairman, said he was ‘cautiously optimistic’ that there would be solutions for the disease in the near future.
LiveTalk: Where’s Our Alzheimer’s Cure?
Karl Herrup on What’s Taking So Long
Here’s where you can read more.